Become a Founding Member for $999 a year, locked for life

    Claim a seat
    MavenlyMavenly

    § Federal grant opportunity · RFA-MH-27-110

    Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks

    National Institutes of Health is accepting applications for Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks. The deadline is Rolling / not published and the published award range is Award amount not published.

    Key facts

    Funder
    National Institutes of Health
    Application deadline
    Rolling / not published
    Award range
    Award amount not published
    Eligibility
    nonprofits non higher education without 501c3, other, independent school districts, federally recognized native american tribal governments, special district governments, private institutions of higher education, for profit organizations other than small businesses, state governments, other native american tribal organizations, city or township governments, public and state institutions of higher education, county governments, public and indian housing authorities, small businesses, nonprofits non higher education with 501c3
    Geography
    United States
    Focus areas
    Health
    Opportunity number
    RFA-MH-27-110

    Program overview

    The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV and to identify mechanisms, benefits, and risks associated with their use in the CNS compartment. The primary goal is to generate evidence that informs whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. By addressing CNS-specific barriers such as blood brain barrier penetration, compartmentalized viral dynamics, and immune-mediated effects, this NOFO will support the development of strategies that contribute to sustained virologic remission across anatomical compartments and improve long-term neurologic and cognitive outcomes in people with HIV. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into the impact of HIV immunotherapies on the CNS and viral reservoirs are strongly encouraged to apply to this new NOFO. This NOFO will utilize the R21/R33 activity code.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from National Institutes of Health.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before Rolling / not published, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.